Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRL1 | P41146 | 11/20 | 0.61 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.43 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.39 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.39 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.38 |
| ▸ | HSD11B1 | P28845 | 3/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1690157 | 0.94 | OPRL1 (0.55) | OPRL1CYP11B2OPRM1RIPK1 | |
| SCHEMBL364660 | 0.90 | OPRL1 (0.57) | OPRL1OPRM1RIPK1 | |
| Potassium SCHEMBL29930080 | 0.88 | OPRL1 (0.56) | OPRL1OPRM1RIPK1 | |
| SCHEMBL13239364 | 0.81 | SLC6A4 (0.54) | OPRL1 | |
| SCHEMBL21038284 | 0.79 | OPRL1 (0.46) | OPRL1OPRM1 | |
| SCHEMBL30416757 | 0.79 | OPRL1 (0.49) | OPRL1OPRM1HSD11B1 | |
| SCHEMBL25053737 | 0.78 | CYP11B2 (0.44) | OPRL1CYP11B2OPRM1KDM4EGAA | |
| SCHEMBL1253356 | 0.78 | CYP11B2 (0.44) | OPRL1CYP11B2OPRM1KDM4EGAA | |
| SCHEMBL22940029 | 0.78 | CYP11B2 (0.44) | OPRL1CYP11B2OPRM1KDM4EGAA | |
| SCHEMBL5707046 | 0.78 | CYP11B2 (0.44) | OPRL1CYP11B2OPRM1KDM4EGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011131596-A1 | HETEROARYL-CYCLOHEXYL-TETRAAZABENZO[E]AZULENES AS VASOPRESSIN V1A RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-10-27 | — | — | WO | disclosed |